Praxis Precision Medicines Q3 2024 Earnings Report $78.29 -2.64 (-3.26%) As of 04:00 PM Eastern Earnings HistoryForecast Praxis Precision Medicines EPS ResultsActual EPS-$2.75Consensus EPS -$2.01Beat/MissMissed by -$0.74One Year Ago EPS-$2.70Praxis Precision Medicines Revenue ResultsActual Revenue$0.30 millionExpected Revenue$0.53 millionBeat/MissMissed by -$230.00 thousandYoY Revenue GrowthN/APraxis Precision Medicines Announcement DetailsQuarterQ3 2024Date11/6/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSEC FilingPRAX Earnings History Praxis Precision Medicines Earnings HeadlinesPraxis Precision Medicines to Present at J.P. Morgan Healthcare ConferenceJanuary 6 at 8:23 AM | finance.yahoo.comPraxis Precision files automatic mixed securities shelfDecember 24, 2024 | markets.businessinsider.comBuy this Stock before Trump Takes Office!We're issuing an urgent "buy alert" on a little-known "AI company" set to SOAR under this new administration. And it's not just because it hit a critical "buy now" price.January 6, 2025 | Behind the Markets (Ad)Praxis Precision Medicines (PRAX) Gets a Buy from Truist FinancialDecember 20, 2024 | markets.businessinsider.comPraxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet SyndromeDecember 18, 2024 | finanznachrichten.dePraxis Precision announces U.S. FDA granted RPDD for relutrigineDecember 18, 2024 | markets.businessinsider.comSee More Praxis Precision Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Praxis Precision Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Praxis Precision Medicines and other key companies, straight to your email. Email Address About Praxis Precision MedicinesPraxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.View Praxis Precision Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
